grade
pharmaceutical primary standard
API family
nortriptyline, amitriptyline
manufacturer/tradename
EDQM
refractive index
n20/D 1.6332 (lit.)
bp
148 °C/0.3 mmHg (lit.)
mp
32-34 °C (lit.)
density
1.156 g/mL at 25 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
O=C1c2ccccc2CCc3ccccc13
InChI
1S/C15H12O/c16-15-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)15/h1-8H,9-10H2
InChI key
BMVWCPGVLSILMU-UHFFFAOYSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Dibenzosuberone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under 二苯并环庚酮
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
235.4 °F - closed cup
flash_point_c
113 °C - closed cup
Solveigh C Koeberle et al.
Journal of medicinal chemistry, 55(12), 5868-5877 (2012-06-09)
Synthesis, biological testing, structure-activity relationships (SARs), and selectivity of novel disubstituted dibenzosuberone derivatives as p38 MAP kinase inhibitors are described. Hydrophilic moieties were introduced at the 7-, 8-, and 9-position of the 2-phenylamino-dibenzosuberones, improving physicochemical properties as well as potency.
S P Dixon et al.
Pharmeuropa scientific notes, 2005(1), 15-20 (2007-08-11)
An isocratic reversed-phase liquid chromatographic method is described using a hybrid column for the control of synthetic impurities potentially found in amitriptyline hydrochloride. The method has been validated and is capable of controlling impurities to 0.1 per cent.
Stefan Fischer et al.
Journal of medicinal chemistry, 56(1), 241-253 (2012-12-29)
p38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases. Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market. This might be attributed to the fact that there is no inhibitor
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| D1000000 | 04061833792827 |